ADCT MEXC RealStocks
Own real ADCT shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-12 11:46:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
ADC Therapeutics SA (ADCT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $1.55, with a market capitalization of $212.40M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.78 to $4.98. This page covers its latest market performance, valuation, price trends and company information.
$212.40M | |
$1.59 | |
$1.63 | |
$1.51 | |
$1.60 | |
1.00 | |
1.66M | |
-- | |
$4.98 | |
$0.78 | |
-- | |
-- |
ADC Therapeutics SA (ADCT) is trading at $1.55 in pre-market trading as of 2026-11-12 11:03:00, down 3.06% ($0.05) from the previous close of $1.60
Pre-market trading shows how investors are pricing ADCT before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, ADC Therapeutics SA (ADCT) moved from $1.55 to $1.55, representing a gain of 0.06% ($0.00).
The stock traded between $1.41 and $1.87 during the period. The latest price is near the lower end of the 7-day range, indicating range-bound.
The average daily volume was 1.74 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 18.4%
ADCT is currently trading at $1.55, placing it 18.4% of the way from its 52-week low of $0.78 to its 52-week high of $4.98. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 193 |
| Exchange | NYSE |
| Company Website |
View the latest dividend and stock split events for ADC Therapeutics SA.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of ADC Therapeutics SA (ADCT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ADCT, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ADCT shares and USD.
ADCT Shares to USD
1.00 ADCT shares = 1.551 USD
Calculations are estimates based on the latest available price and are for reference only.